002317 众生药业
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,908,022-7.88%2,610,5502,676,1522,429,0951,895,824
减:营业总成本1,701,672-2.46%2,295,4972,350,0632,102,1031,649,699
    其中:营业成本837,9422.13%1,080,875940,486806,557657,142
               财务费用6,188-64.92%16,78457,22948,3589,294
               资产减值损失(919)--(16,746)(1,083)(7,191)(846,907)
公允价值变动收益5,861-110.70%(65,231)(19,506)(66,731)137,976
投资收益20,84119.71%23,52846,35620,673100,299
    其中:对联营企业和合营企业的投资收益3,3361,005.80%(228)(369)(833)(3,250)
营业利润236,330-25.18%298,731374,263312,661(324,194)
利润总额177,723-43.47%283,657368,302309,478(345,272)
减:所得税费用41,81218.97%33,75652,95434,80889,157
净利润135,911-51.32%249,901315,348274,670(434,429)
减:非控股权益(12,892)4,492.04%(13,372)(6,702)(2,961)(7,822)
股东净利润148,802-46.76%263,273322,050277,631(426,607)

市场价值指针
每股收益 (元) *0.180-47.06%0.3200.4000.350-0.530
每股派息 (元) *----0.2000.2000.2000.200
每股净资产 (元) *5.1500.36%5.1004.5464.2674.328
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容